[1]
Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013 Sep 10:128(11):1256-67. doi: 10.1161/CIRCULATIONAHA.113.000962. Epub
[PubMed PMID: 24019446]
[2]
Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clinical chemistry. 2011 Mar:57(3):392-410. doi: 10.1373/clinchem.2010.155333. Epub 2011 Jan 25
[PubMed PMID: 21266551]
[3]
Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013 Sep 10:128(11):1189-97. doi: 10.1161/CIRCULATIONAHA.113.002671. Epub 2013 Sep 3
[PubMed PMID: 24002795]
[4]
Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, Droste C, Assmann G. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proceedings of the National Academy of Sciences of the United States of America. 1991 Jun 1:88(11):4855-9
[PubMed PMID: 2052566]
[5]
Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Annals of internal medicine. 1995 Jan 15:122(2):133-41
[PubMed PMID: 7992988]
[6]
Yamakawa-Kobayashi K, Yanagi H, Fukayama H, Hirano C, Shimakura Y, Yamamoto N, Arinami T, Tsuchiya S, Hamaguchi H. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Human molecular genetics. 1999 Feb:8(2):331-6
[PubMed PMID: 9931341]
Level 3 (low-level) evidence
[7]
Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature genetics. 1999 Aug:22(4):336-45
[PubMed PMID: 10431236]
[8]
Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature genetics. 1999 Aug:22(4):352-5
[PubMed PMID: 10431238]
[9]
Emmerich J, Vergès B, Tauveron I, Rader D, Santamarina-Fojo S, Shaefer J, Ayrault-Jarrier M, Thiéblot P, Brewer HB Jr. Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arteriosclerosis and thrombosis : a journal of vascular biology. 1993 Sep:13(9):1299-306
[PubMed PMID: 8364014]
[10]
Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. The New England journal of medicine. 2010 Dec 2:363(23):2220-7. doi: 10.1056/NEJMoa1002926. Epub 2010 Oct 13
[PubMed PMID: 20942659]
[11]
Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation. 2000 Oct 31:102(18):2197-203
[PubMed PMID: 11056092]
[12]
Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. The New England journal of medicine. 1998 Jan 8:338(2):86-93
[PubMed PMID: 9420339]
[13]
Tato F, Vega GL, Grundy SM. Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arteriosclerosis, thrombosis, and vascular biology. 1995 Apr:15(4):446-51
[PubMed PMID: 7749855]
[14]
Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992 Jun:85(6):2025-33
[PubMed PMID: 1534286]
[15]
Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999 Jun 8:99(22):2901-7
[PubMed PMID: 10359734]
Level 1 (high-level) evidence
[16]
Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997 Sep 16:96(6):1737-44
[PubMed PMID: 9323055]
[17]
Blades B, Vega GL, Grundy SM. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arteriosclerosis and thrombosis : a journal of vascular biology. 1993 Aug:13(8):1227-35
[PubMed PMID: 8343498]
[18]
Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, Marcovina SM, Funke H, Assmann G, Pritchard PH, Kastelein JJ. A unique genetic and biochemical presentation of fish-eye disease. The Journal of clinical investigation. 1995 Dec:96(6):2783-91
[PubMed PMID: 8675648]
[19]
Klein HG, Lohse P, Pritchard PH, Bojanovski D, Schmidt H, Brewer HB Jr. Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123----Ile) and lecithin-cholesterol acyltransferase (Thr347----Met). The Journal of clinical investigation. 1992 Feb:89(2):499-506
[PubMed PMID: 1737840]
[20]
Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis. 1995 Nov:118(1):111-22
[PubMed PMID: 8579621]
[21]
Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature genetics. 1999 Aug:22(4):347-51
[PubMed PMID: 10431237]
[22]
Ghali WA, Rodondi N. HDL cholesterol and cardiovascular risk. BMJ (Clinical research ed.). 2009 Feb 16:338():a3065. doi: 10.1136/bmj.a3065. Epub 2009 Feb 16
[PubMed PMID: 19221138]
[23]
AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine. 2011 Dec 15:365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15
[PubMed PMID: 22085343]
[24]
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. The New England journal of medicine. 1999 Aug 5:341(6):410-8
[PubMed PMID: 10438259]
[25]
Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001 Mar 28:285(12):1585-91
[PubMed PMID: 11268266]
Level 1 (high-level) evidence
[26]
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013 Oct 1:128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21
[PubMed PMID: 23965489]
Level 1 (high-level) evidence
[27]
Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994 Oct:90(4):1935-41
[PubMed PMID: 7923682]
[28]
Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003 Nov 5:290(17):2292-300
[PubMed PMID: 14600188]
Level 1 (high-level) evidence
[29]
Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13:134(24):1918-1930
[PubMed PMID: 27881559]
[30]
Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J, Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007 Apr 18:297(15):1675-82
[PubMed PMID: 17387133]
Level 1 (high-level) evidence
[31]
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. The New England journal of medicine. 2004 Apr 8:350(15):1505-15
[PubMed PMID: 15071125]
[32]
Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation. 2005 Apr 12:111(14):1847-54
[PubMed PMID: 15824213]
[33]
Gaĭstruk AN. [Acid-base equilibrium and its correction in parturients with arterial hypotension]. Akusherstvo i ginekologiia. 1972 May:48(5):42-4
[PubMed PMID: 5071124]
[34]
Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. Journal of lipid research. 2010 Dec:51(12):3443-54. doi: 10.1194/jlr.M008706. Epub 2010 Sep 22
[PubMed PMID: 20861162]
[35]
Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011 Nov 16:306(19):2099-109. doi: 10.1001/jama.2011.1649. Epub
[PubMed PMID: 22089718]
Level 1 (high-level) evidence
[36]
Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. European heart journal. 2004 May:25(9):771-7
[PubMed PMID: 15120888]
[37]
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (London, England). 2002 Jul 6:360(9326):7-22
[PubMed PMID: 12114036]
Level 1 (high-level) evidence
[38]
Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis. 1988 Nov:74(1-2):85-9
[PubMed PMID: 3214483]
[39]
Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. The New England journal of medicine. 1988 Nov 3:319(18):1173-9
[PubMed PMID: 3173455]
[40]
Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. The New England journal of medicine. 1991 Aug 15:325(7):461-6
[PubMed PMID: 1852180]
[41]
Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. American heart journal. 1983 Nov:106(5 Pt 2):1191-200
[PubMed PMID: 6637784]
[42]
van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJ, Westerink J, Visseren FL, SMART Study Group. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. Journal of the American College of Cardiology. 2013 Nov 12:62(20):1834-41. doi: 10.1016/j.jacc.2013.04.101. Epub 2013 Aug 21
[PubMed PMID: 23948286]
[43]
Qi Y, Fan J, Liu J, Wang W, Wang M, Sun J, Liu J, Xie W, Zhao F, Li Y, Zhao D. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. Journal of the American College of Cardiology. 2015 Feb 3:65(4):355-363. doi: 10.1016/j.jacc.2014.11.019. Epub
[PubMed PMID: 25634834]
Level 2 (mid-level) evidence
[44]
Ahmad S, Moorthy MV, Demler OV, Hu FB, Ridker PM, Chasman DI, Mora S. Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. JAMA network open. 2018 Dec 7:1(8):e185708. doi: 10.1001/jamanetworkopen.2018.5708. Epub 2018 Dec 7
[PubMed PMID: 30646282]
[45]
Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. The Cochrane database of systematic reviews. 2019 Mar 13:3(3):CD009825. doi: 10.1002/14651858.CD009825.pub3. Epub 2019 Mar 13
[PubMed PMID: 30864165]
Level 1 (high-level) evidence
[46]
Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ (Clinical research ed.). 2008 Sep 11:337():a1344. doi: 10.1136/bmj.a1344. Epub 2008 Sep 11
[PubMed PMID: 18786971]
Level 1 (high-level) evidence
[47]
Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. International journal of cancer. 2014 Oct 15:135(8):1884-97. doi: 10.1002/ijc.28824. Epub 2014 Mar 11
[PubMed PMID: 24599882]
Level 1 (high-level) evidence
[48]
Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. European journal of clinical nutrition. 2009 May:63 Suppl 2():S22-33. doi: 10.1038/sj.ejcn.1602976. Epub
[PubMed PMID: 19424216]
[49]
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. The American journal of clinical nutrition. 2003 May:77(5):1146-55
[PubMed PMID: 12716665]
Level 1 (high-level) evidence
[50]
Ryan M, McInerney D, Owens D, Collins P, Johnson A, Tomkin GH. Diabetes and the Mediterranean diet: a beneficial effect of oleic acid on insulin sensitivity, adipocyte glucose transport and endothelium-dependent vasoreactivity. QJM : monthly journal of the Association of Physicians. 2000 Feb:93(2):85-91
[PubMed PMID: 10700478]
[51]
Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arteriosclerosis and thrombosis : a journal of vascular biology. 1992 Aug:12(8):911-9
[PubMed PMID: 1386252]
Level 1 (high-level) evidence
[52]
Valero-Elizondo J, Aneni EC, Osondu CU, Grandhi GR, Virani SS, Nasir K. Gaps in provider lifestyle counseling and its adherence among obese adults with prediabetes and diabetes in the United States. Preventive medicine. 2019 Dec:129():105815. doi: 10.1016/j.ypmed.2019.105815. Epub 2019 Aug 24
[PubMed PMID: 31454663]
[53]
Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health services research. 2007 Oct:42(5):1871-94
[PubMed PMID: 17850524]